March 24, 2026

Haemonetics Corporation (HAE) Stock Analysis: Exploring a 49.67% Potential Upside in the Medical Device Sector

Haemonetics Corporation (NYSE: HAE), a prominent player in the healthcare sector, is a medical technology company with a strong presence in the medical devices industry. With a market capitalization of..

HUTCHMED (China) Limited (HCM): Growth Potential with a 53% Upside and Strong Analyst Support

HUTCHMED (China) Limited (HCM), a prominent player in the healthcare sector, particularly within the drug manufacturing industry, is capturing investor attention with its potential growth trajectory and robust analyst endorsement...

Organon & Co. (OGN) Stock Analysis: Understanding the 47.78% Potential Upside in a Turbulent Market

As investors explore the dynamics of the healthcare sector, Organon & Co. (NYSE: OGN) presents a compelling narrative. With its roots in Jersey City, New Jersey, Organon has carved out..

Arcellx, Inc. (ACLX) Stock Analysis: Navigating the Biotech Landscape with a $6.7 Billion Market Cap

Arcellx, Inc. (ACLX), a rising star in the biotechnology sector, is making waves with its ambitious pipeline focused on innovative immunotherapies. Headquartered in Redwood City, California, Arcellx is carving its..

Alvotech (ALVO) Stock Analysis: Exploring a 365% Upside Potential in the Biosimilar Market

Alvotech (NASDAQ: ALVO), a Luxembourg-based healthcare company specializing in biosimilar medicines, presents a compelling opportunity for investors seeking exposure to the burgeoning biosimilars market. With a market capitalization of $1.04..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 53% Upside Potential

MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company headquartered in Zug, Switzerland, is garnering attention for its innovative approach to treating inflammatory skin and joint diseases. With a market capitalization..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Exploring a Promising 50% Upside Potential

LifeStance Health Group, Inc. (NASDAQ: LFST), a prominent player in the healthcare sector, specifically within the medical care facilities industry, is capturing investor attention with its compelling growth narrative and..

Privia Health Group, Inc. (PRVA) Stock Analysis: Exploring a 48% Upside Potential in the Healthcare Sector

Privia Health Group, Inc. (NASDAQ: PRVA) stands at the forefront of the healthcare sector, providing innovative solutions within the health information services industry. With a market capitalization of $2.66 billion,..

Apogee Therapeutics (APGE) Stock Analysis: Strong Buy Ratings and a 31.67% Upside Potential

Apogee Therapeutics, Inc. (NASDAQ: APGE), a clinical-stage biotechnology firm, is attracting significant attention from investors, thanks to its innovative pipeline and promising analyst ratings. With a market capitalization of $5.46..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Unpacking the 45% Potential Upside in Biotech

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is making waves in the biotechnology sector with its promising pipeline of neurological and psychiatric treatments. The Canadian company, boasting a market capitalization of $5.19..

Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Biotech with Promising 28.43% Upside Potential

Scholar Rock Holding Corporation (NASDAQ: SRRK) is capturing investor attention with its considerable potential upside of 28.43%, according to analyst ratings. As a biopharmaceutical company dedicated to transforming the treatment..

ICU Medical, Inc. (ICUI) Stock Analysis: Exploring a 40.59% Potential Upside with Strong Buy Ratings

ICU Medical, Inc. (NASDAQ: ICUI), a stalwart in the healthcare sector specializing in medical instruments and supplies, has piqued investor interest with its promising growth potential. The company, headquartered in..

Asian markets find firmer footing as easing tensions support risk appetite

A rebound across Asia suggests investors are becoming more constructive again as immediate fears over conflict and energy disruption begin to ease...

Commercial real estate positions for a transitional phase in 2026

A transitional market is encouraging investors to prioritise asset quality, pricing discipline and long-term income resilience...

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing..

Chesnara delivers record 2025 performance amid major acquisitions

Full-year results highlight double-digit growth across key metrics, strengthened capital position, and continued M&A momentum, with a 6% dividend increase proposed...

Nuformix Secures US Orphan Status for NXP002 as Licensing Talks Advance (video)

Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions,..

Trustpilot appoints Marcus Roy as CFO, succeeding Hanno Damm

Trustpilot has named Marcus Roy as Chief Financial Officer, effective September 2026. He joins from The Economist Group and will succeed long-serving CFO Hanno Damm, who will remain briefly to..

Kingfisher reports profit growth and market share gains in FY 2025/26

Kingfisher delivered modest sales growth and improved margins in FY 2025/26, supported by strong UK performance, expansion in trade and e-commerce, and disciplined cost control. Adjusted pre-tax profit rose 6%..

Corero Network Security delivers strong ARR growth and sales momentum in FY25

Corero reported FY 2025 revenue growth and a 23% rise in recurring revenue, driven by strong demand for its DDoS protection solutions and robust second-half performance...
Search

Funds

March 24, 2026

Asian markets find firmer footing as easing tensions support risk appetite

A rebound across Asia suggests investors are becoming more constructive again as immediate fears over conflict and energy disruption begin to ease...

Commercial real estate positions for a transitional phase in 2026

A transitional market is encouraging investors to prioritise asset quality, pricing discipline and long-term income resilience...

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing and non-dilutive backing, the company is advancing its mission to tackle age-related diseases at the genetic level...

Chesnara delivers record 2025 performance amid major acquisitions

Full-year results highlight double-digit growth across key metrics, strengthened capital position, and continued M&A momentum, with a 6% dividend increase proposed...

Nuformix Secures US Orphan Status for NXP002 as Licensing Talks Advance (video)

Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions, the company is positioning itself to advance a differentiated inhaled therapy while negotiating from strength...

Trustpilot appoints Marcus Roy as CFO, succeeding Hanno Damm

Trustpilot has named Marcus Roy as Chief Financial Officer, effective September 2026. He joins from The Economist Group and will succeed long-serving CFO Hanno Damm, who will remain briefly to support the transition...

Kingfisher reports profit growth and market share gains in FY 2025/26

Kingfisher delivered modest sales growth and improved margins in FY 2025/26, supported by strong UK performance, expansion in trade and e-commerce, and disciplined cost control. Adjusted pre-tax profit rose 6% and free cash flow remained solid, with further shareholder returns announced...

Corero Network Security delivers strong ARR growth and sales momentum in FY25

Corero reported FY 2025 revenue growth and a 23% rise in recurring revenue, driven by strong demand for its DDoS protection solutions and robust second-half performance...
Search

Funds

March 24, 2026

FTSE 100

Funds